These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38258034)

  • 21. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
    Paton DM
    Drugs Today (Barc); 2017 Apr; 53(4):239-245. PubMed ID: 28492291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
    Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
    J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
    Dalamaga M; Karampela I; Mantzoros CS
    Metabolism; 2020 Aug; 109():154282. PubMed ID: 32497535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
    Page CP; Spina D
    Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis.
    Hiyama H; Arichika N; Okada M; Koyama N; Tahara T; Haruta J
    J Pharmacol Exp Ther; 2023 Jul; 386(1):45-55. PubMed ID: 37041087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Kang Q; Chen JS; Yang H
    Front Immunol; 2022; 13():1021537. PubMed ID: 36300119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
    Oehrl S; Prakash H; Ebling A; Trenkler N; Wölbing P; Kunze A; Döbel T; Schmitz M; Enk A; Schäkel K
    J Dermatol Sci; 2017 Aug; 87(2):110-115. PubMed ID: 28499587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
    Jin SL; Ding SL; Lin SC
    Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atopic dermatitis: a review of topical nonsteroid therapy.
    Papier A; Strowd LC
    Drugs Context; 2018; 7():212521. PubMed ID: 29632548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
    Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
    JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
    Guttman-Yassky E; Hanifin JM; Boguniewicz M; Wollenberg A; Bissonnette R; Purohit V; Kilty I; Tallman AM; Zielinski MA
    Exp Dermatol; 2019 Jan; 28(1):3-10. PubMed ID: 30332502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.
    Schett G; Sloan VS; Stevens RM; Schafer P
    Ther Adv Musculoskelet Dis; 2010 Oct; 2(5):271-8. PubMed ID: 22870453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is PDE4 too difficult a drug target?
    Higgs G
    Curr Opin Investig Drugs; 2010 May; 11(5):495-8. PubMed ID: 20419594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
    J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M; Papp K
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis.
    Nicolas SE; Bear MD; Kanaan AO; Coman OA; Dima L
    Am J Ther; 2023 Nov-Dec 01; 30(6):e535-e542. PubMed ID: 37921681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.